Open Pharma position statement on open access

Pharmaceutical companies, which fund approximately half of all biomedical research,¹ are now leaders in the publication and disclosure of research.²⁻³ However, access to much company-funded research is restricted by journal paywalls.⁴ We, as Open Pharma, a group of pharmaceutical companies and other research funders, alongside healthcare professionals, regulators, patients, publishers and other stakeholders in healthcare, recognize the importance of publishing research with open access, where papers can be read without payment of a one-off access charge or subscription. Open access ensures that the highest quality, peer-reviewed evidence is available to anyone who needs it, anywhere in the world. Publishing with open access improves transparency, advances medical science and, we believe, ultimately improves patient care.

Our immediate priority

Our immediate priority is to secure authors publishing company-funded research the same right to publish open access as authors publishing research funded by other sources, so that all research can be made free to read from the date of publication. This would enable pharmaceutical companies to follow the lead of other research funders in requiring all the research they fund to be published with open access, without impacting on journal choice.⁵⁻⁷ In order to provide publishers the time to adapt their policies and protect their copyright interests, any variant of Creative Commons or equivalent licence could be used.

Our long-term goal

Our long-term goal is to secure authors publishing company-funded research the same terms as authors publishing research funded by other sources, so that all research can be made free to read – and reuse – from the date of publication. This would enable pharmaceutical companies to follow the lead of other research funders in maximizing the impact of the research they fund on patient health. Open Pharma is committed to working closely with publishers and pharmaceutical companies to ensure that the gold standard Creative Commons Attribution (CC BY) licence can sustainably be used.⁸

Acknowledgements

This Open Pharma position statement on open access represents the opinions of the individual members: Catherine Skobe (Pfizer), Chris Rains (Takeda), Chris Winchester (Oxford PharmaGenesis), Julie Newman (Gilead), Lise Baltzer (Novo Nordisk), Sarah Sabir (Oxford PharmaGenesis) and Valerie Philippon (Takeda), and not necessarily those of their individual companies. We thank the members, supporters and followers of Open Pharma for their input and valuable discussion.

https://doi.org/10.6084/m9.figshare.10003304
References


Endorsements

Publishers
Betasciencepress Publishing
eccancer
F1000 Research Ltd.
Wiley

Organizations
Ataxia & Me
Autoinflammatory UK
Cambridge Rare Disease Network
Galapagos NV
International Kidney Cancer Coalition
Kidney Research UK
Observational and Pragmatic Research Institute Pte
Oxford Health Policy Forum
Oxford PharmaGenesis
Pedalling4ACure
Solanum Medical Communications Ltd.
SUDEP Action
The Aarskog Foundation
ThinkSCIENCE, Inc.
Zimbabwe Evidence Informed Policy Network

Individuals
Mary Kunjappu, Alexion Pharmaceuticals
Kenneth Pomerantz, Alexion Pharmaceuticals
Alan Thomas, Ataxia & Me
Scott Armit, Ataxia & Me
Roland J.W. Meesters, Betasciencepress Publishing
E. Andrew Balas, Biomedical Research Innovation Laboratory, Augusta University
John Wallace, Autoinflammatory UK
Gavin Giovannoni, Barts and the London School of Medicine and Dentistry
Val Tate, communications consultant
Katie Foxall, eccancer
Linda Edmonson, Innovative Strategic Communications
Martin Delahunty, Inspiring STEM
Alben Sigamani, Narayana Health

https://doi.org/10.6084/m9.figshare.10003304
Michael De Rosa, National Ataxia Foundation
Peter Llewellyn, NetworkPharma Ltd.
Pali Hungin, Newcastle University
Klaus Boberg, Novo Nordisk
Serena Vanzan, Oxford Brookes University
Kajsa Wilhelmsson, Oxford Health System Reform Group
Adele Buss, Oxford PharmaGenesis
Alison Hillman, Oxford PharmaGenesis
Cassy Fiford, Oxford PharmaGenesis
Emma Bolton, Oxford PharmaGenesis
Francesca Ounsworth, Oxford PharmaGenesis
Jessica Hardy, Oxford PharmaGenesis
Mark Rolfe, Oxford PharmaGenesis
Nicolas Bertheleme, Oxford PharmaGenesis
Paul Farrow, Oxford PharmaGenesis
Richard White, Oxford PharmaGenesis
Sally Bardell, Oxford PharmaGenesis
Steph Macdonald, Oxford PharmaGenesis
Tim Ellison, Oxford PharmaGenesis
Tim Koder, Oxford PharmaGenesis
Zoe Watts, Oxford PharmaGenesis
Charles Boyce, patient
Emily Medina, patient
Jeannie Smithball, patient
Danielle Grover, patient advocate
Elizabeth Kinder, patient advocate
Richard Stephens, patient advocate
Tracy Zervakis, patient advocate
Trishna Bharadia, patient advocate
Rosario Strano, Pedalling4Cure
Angela Sykes, Pfizer
Courtney Leo, Pfizer
J.R. Meloro, Pfizer
Ellie Challis, PTEN UK & Ireland
Dermot Ryan, Respiratory Effectiveness Group
Victoria Woods, Patient and Public Engagement, Thames Valley Cancer Alliance at NHS England
Sophie Berry, Smith & Nephew
John Gonzalez, Solanum Medical Communications Ltd.
Zbys Fedorowicz, The Care Combine and North West Anglia NHS Foundation Trust
Stuart Taylor, The Royal Society

https://doi.org/10.6084/m9.figshare.10003304
Erik Michels, UCB
Rachel Giles, Regenerative Medicine Center, UMC Utrecht
Meredith Hays, Department of Medicine, Uniformed Services University
Martin Rossor, University College London
Stephen Bradley, University of Leeds
Robert Sim, Department of Respiratory Science, University of Leicester
Iain Chalmers, Centre for Evidence-Based Medicine, University of Oxford
Edith Sim, Department of Pharmacology, University of Oxford
Chas Bountra, Nuffield Department of Clinical Medicine, University of Oxford
Stevan Harnad, University of Southampton
Álvaro Díaz, Departamento de Biociencias, Universidad de la República, Uruguay
Ronald Munatsi, Zimbabwe Evidence Informed Policy Network

Endorsements last updated on 11 November 2019